Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013. The projected 15 percent annual growth rate is attributed to a growing prevalent and drug-treated population, increased use of new generation antidiabetics such as Merck's Januvia, Novartis's Galvus, Sanofi-Aventis's Lantus and Novo Nordisk's Levemir and the launch of several novel agents like Amylin/Eli Lilly/Alkermes's Byetta LAR.

"Throughout our forecast period, sales will be driven by the uptake of newer generation antidiabetics, including dipeptidyl peptidase IV (DPP-IV) inhibitors -- such as Januvia and Galvus as well as fixed-dose combinations containing these agents -- and insulin analogues such as Lantus and Levemir. The anticipated launch of Byetta LAR, which offers greater weight loss and better efficacy in reducing glycosylated hemoglobin (HbA1c) but requires less frequent dosing than Byetta, will also drive sales. Because these drugs have no generic competitors in Brazil and enjoy premium pricing, a slight increase in use will drive rapid growth in revenue," stated Jing Wu, M.S., MBA, analyst at Decision Resources.

The new Emerging Markets report entitled Type 2 Diabetes in Brazil also finds that diagnosis rates of type 2 diabetes in Brazil are far lower than diagnosis rates in major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan). One of the key reasons for this is low disease awareness and poor understanding of type 2 diabetes symptoms among patients, which prevents them from seeking treatment.

"This challenge in diagnosis rates of type 2 diabetes in Brazil is a great opportunity for Western drug companies. Western drug companies should reach out and work with the Brazilian government and policy makers to launch programs that raise disease awareness and promote patient education among the general population in Brazil. These programs can also provide patients with more information on the latest novel therapeutic agents and lead to increased drug sales by multinational drug companies," added Ms. Wu.

The new report contains primary research of physicians and epidemiology study in key pharmaceutical markets of Brazil -- Rio de Janeiro, Sao Paulo, Brasilia and Belo Horizonte.

About Emerging Markets Reports

Decision Resources offers a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:       Gisselle Morales                             Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563             

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Gisselle Morales of Decision Resources, +1-781-296-2691,; or Elizabeth Marshall of Decision Resources, Inc.,

Most Surveyed Clinicians Will Prescribe Amgen/GlaxoSmithKline's Prolia as Either a Second- or Third-Line Therapy for Osteoporosis

View Now